Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri,
M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January.

Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. The company would
like to thank Mr Kvam for his valuable work and dedication over the past years.
"During his seven years in  Oncoinvent, Tore Kvam has worked tirelessly to
contribute to Oncoinvent's development and  performance. We're very grateful for
his contribution," says Øystein Soug, CEO of Oncoinvent.

Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as
Vice President and Head of Development Strategy & Execution. He brings broad
international experience through  leadership positions in strategy, operations,
and corporate transformation across the life sciences  and healthcare
industries. Dr. Amri also brings seven years of management consulting
experience  from McKinsey & Company, advising global pharma and biotech clients,
as well as financial  institutions and private-equity-backed businesses, on
growth, M&A, and organizationaltransformation.

Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He
conducted his Ph.D.  research and completed a postdoctoral fellowship in
surgical oncology and epidemiology at Harvard Medical School and Massachusetts
General Hospital, where he initiated and led a research program in colorectal
cancer.

"We are pleased to welcome Dr. Amri to Oncoinvent's management team," says
Øystein Soug, CEOof Oncoinvent. "His strategic and financial leadership,
together with deep industry knowledge, will be instrumental as we advance our
clinical programs and continue building long-term value for patients  and
shareholders alike."

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical  therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting  radionuclide radium-224, directly
targeting micro-metastases in the peritoneum post-surgery,  harnessing the
benefits of modern radiopharmaceuticals without the complexities of biological
targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in
a clinical  development program in two indications. One Phase 1 trial and one
Phase 1/2a trial have been  completed and one randomized Phase 2 trial in
ovarian cancer is currently ongoing in the US and  Europe. Early clinical
efficacy data are highly encouraging, and no serious toxicity or safety concerns
have been reported to date. Oncoinvent runs a state-of-the-art manufacturing
facility to produce  drug products for clinical trials in Nydalen, Oslo.
Oncoinvent is listed on the Oslo Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly
target microscopic  metastases in the abdominal cavity following surgery.
Radspherin® is currently in development as a  post-surgical treatment for
patients with cancer that has spread to the abdominal cavity - a group  with
very limited treatment options today. The drug candidate offers a distinctly
unique therapeutic approach with several differentiating features, including the
use of radium-224, single-dose  treatment with a sustained therapeutic effect,
non-systemic administration, direct targeting and an  exceptional dose-to-tumor
ratio, maximizing efficacy while limiting harm to healthy tissue

Forward-Looking Statements

All statements other than statements of historical facts contained in this press
release are forward- looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations  will be achieved. These forward
-looking statements represent Oncoinvent's expectations as of the  date of this
press release, and Oncoinvent disclaims any obligation to update the forward
-looking  statements. These forward-looking statements are subject to known and
unknown risks and  uncertainties that may cause actual results to differ
materially, including with respect to whether the results of clinical or other
studies will support the use of our product offerings, the impact of results  of
such studies, our expectations of the reliability, accuracy and performance of
our tests, or of the  benefits of our tests and product offerings to patients,
providers and payers.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email:soug@oncoinvent.com  (soug@oncoinvent.com)